Arsenic-Containing Medicine Treatment Disturbed the Human Intestinal Microbial Flora
Toxics · 15.05.2023 · 11 (5) · 458
DOI: 10.3390/toxics11050458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxics, online erschienen am 15.05.2023. Verfasst von Jiaojiao Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Ecology and Environmental Sciences & Yunnan Key Laboratory for Plateau Mountain Ecology and Restoration of Degraded Environments, Yunnan U…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Yunnan Provincial Science and Technology Department.
Abstract (Originalsprache)
Human intestinal microbiome plays vital role in maintaining intestinal homeostasis and interacting with xenobiotics. Few investigations have been conducted to understand the effect of arsenic-containing medicine exposure on gut microbiome. Most animal experiments are onerous in terms of time and resources and not in line with the international effort to reduce animal experiments. We explored the overall microbial flora by 16S rRNA genes analysis in fecal samples from acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA). Gut microbiomes were found to be overwhelmingly dominated by Firmicutes and Bacteroidetes after taking medicines containing arsenic in APL patients. The fecal microbiota composition of APL patients after treatment showed lower diversity and uniformity shown by the alpha diversity indices of Chao, Shannon, and Simpson. Gut microbiome operational taxonomic unit (OTU) numbers were associated with arsenic in the feces. We evaluated Bifidobacterium adolescentis and Lactobacillus mucosae to be a keystone in APL patients after treatment. Bacteroides at phylum or genus taxonomic levels were consistently affected after treatment. In the most common gut bacteria Bacteroides fragilis, arsenic resistance genes were significantly induced by arsenic exposure in anaerobic pure culture experiments. Without an animal model, without taking arsenicals passively, the results evidence that arsenic exposure by drug treatment is not only associated with alterations in intestinal microbiome development at the abundance and diversity level, but also induced arsenic biotransformation genes (ABGs) at the function levels which may even extend to arsenic-related health outcomes in APL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Ecology and Environmental Sciences & Yunnan Key Laboratory for Plateau Mountain Ecology and Restoration of Degraded Environments, Yunnan University, Kunming 650500, China.
- Hematology Department of First People's Hospital of Yunnan Province, Kunming 650032, China.
- Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
- Institute of Environmental Remediation and Human Health, College of Ecology and Environment, Southwest Forestry University, Kunming 650224, China.
ORCID-Profile: Jiaojiao Li
Förderung
- National Natural Science Foundation of China
- Yunnan Provincial Science and Technology Department
Zitieren
APA
Li, J., Chen, X., Zhao, S., & Chen, J. (2023). Arsenic-Containing Medicine Treatment Disturbed the Human Intestinal Microbial Flora. Toxics, 11(5), 458. https://doi.org/10.3390/toxics11050458
Vancouver
Li J, Chen X, Zhao S, Chen J. Arsenic-Containing Medicine Treatment Disturbed the Human Intestinal Microbial Flora. Toxics. 2023;11(5):458. doi:10.3390/toxics11050458
BibTeX
@article{Li2023,
author = {Li, Jiaojiao and Chen, Xinshuo and Zhao, Shixiang and Chen, Jian},
title = {Arsenic-Containing Medicine Treatment Disturbed the Human Intestinal Microbial Flora},
journal = {Toxics},
year = {2023},
volume = {11},
number = {5},
pages = {458},
doi = {10.3390/toxics11050458}
}
EUVIMED